AbbVie’s once-daily Parkinson’s pill receives FDA approval

AbbVie announced that the U.S. Food and Drug Administration has granted approval for its once‑daily oral therapy for Parkinson’s disease. The decision allows the product to be marketed in the United States.

The approval was based on data from a late‑stage clinical trial that demonstrated the medication improved motor symptoms in participants. The study met the agency’s efficacy and safety requirements.

The clearance adds a new treatment option for patients with Parkinson’s and highlights AbbVie’s continued focus on neurology therapeutics.